| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 137 | 155 | 159 | 180 | 166 | 179 | 185 | 178 | 175 | 203 | 209 | 221 | 223 | 237 | 238 | 266 | 254 | 284 | 300 | 316 | 335 | 352 | 357 | 393 | 402 | 447 | 448 | 467 |
| Expenses | 103 | 116 | 125 | 139 | 125 | 132 | 135 | 131 | 125 | 143 | 146 | 159 | 157 | 173 | 179 | 202 | 202 | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 | 321 |
| EBITDA | 35 | 39 | 35 | 41 | 41 | 47 | 50 | 47 | 50 | 60 | 63 | 63 | 66 | 64 | 59 | 64 | 51 | 74 | 86 | 92 | 101 | 99 | 108 | 112 | 121 | 142 | 138 | 146 |
| Operating Profit % | 23 % | 23 % | 20 % | 20 % | 23 % | 24 % | 25 % | 23 % | 27 % | 28 % | 28 % | 25 % | 26 % | 23 % | 22 % | 22 % | 19 % | 24 % | 25 % | 27 % | 27 % | 25 % | 27 % | 26 % | 27 % | 27 % | 27 % | 27 % |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 10 | 11 | 10 | 11 | 11 | 13 | 13 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 22 | 21 |
| Interest | 4 | 7 | -1 | 2 | 3 | 2 | 5 | 8 | 3 | 3 | 5 | -2 | 3 | 0 | -1 | 2 | 1 | 0 | 5 | 2 | 3 | 2 | 4 | 3 | 3 | 3 | 3 | 2 |
| Profit Before Tax | 22 | 23 | 26 | 30 | 28 | 36 | 34 | 29 | 36 | 46 | 46 | 52 | 50 | 50 | 46 | 49 | 36 | 59 | 67 | 75 | 83 | 81 | 88 | 93 | 99 | 118 | 113 | 123 |
| Tax | 9 | 9 | 10 | 8 | 8 | 7 | 9 | 6 | 10 | 11 | 11 | 13 | 13 | 12 | 11 | 13 | 9 | 16 | 17 | 16 | 20 | 19 | 23 | 24 | 24 | 31 | 28 | 31 |
| Net Profit | 13 | 15 | 16 | 22 | 20 | 28 | 25 | 23 | 27 | 35 | 35 | 39 | 38 | 38 | 35 | 36 | 27 | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 | 92 |
| EPS in ₹ | 1.50 | 1.65 | 1.82 | 2.44 | 2.24 | 3.22 | 2.83 | 2.57 | 3.03 | 3.97 | 4.00 | 4.26 | 3.92 | 3.99 | 3.60 | 3.77 | 2.81 | 4.53 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 9.01 | 8.48 | 8.92 |
Poly Medicure
2,258.60
-26.20
(-1.15%)
Market Cap
23,150.90 Cr
EPS
26.92
PE Ratio
68.44
Dividend Yield
0.15 %
Industry
Healthcare52 Week High
3,357.80
52 Week Low
1,585.60
PB Ratio
8.38
Debt to Equity
0.12
Sector
Medical Equipment
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
2,258.60 | #1 23,150.90 | #7 68.44 | #1 1,434.50 | #4 24.59 | #1 258 | #4 34.21 | 38.49 | |
383.75 | 2,052.00 | 76.78 | 195.30 | 19.23 | 18 | -44.16 | 45.06 | |
376.55 | 2,045.20 | 68.74 | 307.90 | -0.45 | 43 | -0.97 | 47.36 | |
603.45 | 997.50 | 58.78 | 173.30 | 40.00 | 15 | -34.92 | 45.16 | |
486.40 | 585.00 | 32.21 | 59.30 | 30.58 | 16 | 6.25 | 52.35 | |
270.95 | 433.40 | 21.62 | 132.70 | #1 61.83 | 13 | - | 59.60 | |
163.25 | 292.30 | 18.14 | 65.60 | -16.22 | 4 | - | 74.40 | |
255.52 | 250.50 | 296.76 | 122.10 | 19.24 | 1 | 159.52 | 59.08 | |
88.65 | 164.20 | #1 15.97 | 122.60 | 16.98 | 9 | 45.83 | 47.15 | |
150.80 | 151.30 | 18.92 | 101.10 | 0.60 | 2 | #1 841.20 | 64.63 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
24.59 %
Net Income Growth
44.06 %
Cash Flow Change
39.27 %
ROE
21.68 %
ROCE
22.93 %
EBITDA Margin (Avg.)
11.00 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 |
| Fixed Assets | 166 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 |
| Current Assets | 160 | 171 | 205 | 255 | 302 | 318 | 704 | 783 | 807 | 842 |
| Capital Work in Progress | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 |
| Investments | 0 | 0 | 3 | 17 | 8 | 25 | 354 | 346 | 132 | 167 |
| Other Assets | 189 | 191 | 227 | 264 | 321 | 354 | 422 | 499 | 732 | 749 |
| Total Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 |
| Current Liabilities | 113 | 109 | 114 | 123 | 154 | 193 | 171 | 227 | 293 | 351 |
| Non Current Liabilities | 55 | 50 | 72 | 104 | 119 | 139 | 87 | 63 | 42 | 37 |
| Total Equity | 196 | 229 | 272 | 338 | 381 | 435 | 966 | 1,088 | 1,242 | 1,470 |
| Reserve & Surplus | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 |
| Share Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 |
| Investing Activities | -59 | -31 | -56 | -88 | -101 | -107 | -436 | -85 | -179 | -241 |
| Operating Activities | 63 | 63 | 56 | 75 | 107 | 128 | 119 | 124 | 191 | 266 |
| Financing Activities | -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 |
Share Holding
| % Holding | Feb 2021 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Aug 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 44.88 % | 44.88 % | 44.77 % | 44.77 % | 44.76 % | 44.66 % | 53.34 % | 53.33 % | 53.33 % | 53.31 % | 53.31 % | 53.16 % | 53.16 % | 53.15 % | 66.03 % | 62.56 % | 62.56 % | 62.44 % | 62.44 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.49 % | 0.00 % | 12.38 % | 9.91 % | 11.10 % | 11.87 % | 12.33 % | 11.46 % |
| DIIs | 1.83 % | 1.92 % | 2.68 % | 2.73 % | 2.86 % | 3.18 % | 3.10 % | 3.20 % | 3.38 % | 3.68 % | 4.25 % | 5.15 % | 5.28 % | 7.22 % | 9.35 % | 12.48 % | 12.33 % | 11.66 % | 11.96 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 15.11 % | 14.24 % | 13.69 % | 13.24 % | 12.32 % | 11.93 % | 11.20 % | 11.18 % | 11.12 % | 11.10 % | 11.35 % | 11.38 % | 11.34 % | 11.37 % | 10.70 % | 10.14 % | 10.55 % | 11.08 % |
| Others | 37.06 % | 38.10 % | 38.30 % | 38.81 % | 39.14 % | 39.84 % | 31.63 % | 32.27 % | 32.11 % | 31.90 % | 31.34 % | 15.85 % | 30.17 % | 15.92 % | 3.36 % | 3.16 % | 3.10 % | 3.03 % | 3.07 % |
| No of Share Holders | 0 | 19,187 | 21,531 | 35,922 | 33,678 | 35,166 | 33,831 | 33,296 | 34,239 | 35,393 | 36,141 | 34,649 | 36,053 | 36,712 | 36,852 | 40,516 | 38,352 | 60,686 | 65,583 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2.5 | 2 | 2 | 2 | 2.5 | 2.5 | 3 | 3 | 0.00 |
| Dividend Yield (%) | 0.00 | 1 | 0.91 | 0.86 | 0.24 | 0.26 | 0.27 | 0.19 | 0.13 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 06 May 2025 |  Quarterly Result Announcement | NA | 06 May 2025 | 2,588.50 | 2,591.10 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 2,442.30 | 2,428.85 |
| 28 Oct 2024 | Quarterly Result Announcement | NA | 28 Oct 2024 | 2,452.50 | 2,515.05 |
| 26 Sept 2024 |  Annual General Meeting | NA | 26 Sept 2024 | 2,502.15 | 2,317.00 |
| 20 Sept 2024 |  Dividend | ₹ 3.00 /share | 19 Sept 2024 | 1,653.80 | 2,465.30 |
| 22 Sept 2023 | Dividend | ₹ 3.00 /share | 21 Sept 2023 | 978.85 | 1,411.50 |
| 19 Sept 2022 | Dividend | ₹ 2.50 /share | 16 Sept 2022 | 717.35 | 929.70 |
| 17 Sept 2021 | Dividend | ₹ 2.50 /share | 16 Sept 2021 | 1,136.45 | 956.25 |
| 28 Mar 2017 |  Bonus | 1:1 | 24 Mar 2017 | 0.00 | 0.00 |
Announcements
Statement Of Deviation & Variation - 31St March 2025
May 15, 2025
May 15, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Resignation of DirectorMay 06, 2025
May 06, 2025Re-Appointment Of Internal Auditors
Appointment Of Secretarial AuditorMay 06, 2025
May 06, 2025Audited Standalone & Consolidated Financial Results For The Quarter And Year Ended 31.03.2025May 06, 2025
May 06, 2025Board Meeting Outcome for Outcome Of The Board Meeting Of The Company In Compliance Of Regulation 30 And 33 Of SEBI (LODR) Regulations 2015
May 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 03, 2025
May 03, 2025Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 06Th May 2025.Apr 29, 2025
Apr 29, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Apr 14, 2025Closure of Trading WindowMar 31, 2025
Mar 31, 2025Intimation Of Receiving The Medical Device Regulation (MDR) Certification In Europe For 54 ProductsMar 11, 2025
Mar 11, 2025Statement Of Deviation(S) Or Variation(S) For The Quarter Ended 31St December 2024.Feb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-AcquisitionFeb 05, 2025
Feb 05, 2025Integrated Filing (Financial)Feb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 03, 2025
Feb 03, 2025Unaudited Financial Results (Standalone & Consolidated) For The Third Quarter And Nine Months Ended On 31St December 2024Feb 03, 2025
Feb 03, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On Today I.E. 03Rd February 2025Feb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 29, 2025
Jan 29, 2025Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On 03Rd February 2025Jan 27, 2025
Jan 27, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJan 25, 2025
Jan 25, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 14, 2025
Jan 14, 2025Announcement under Regulation 30 (LODR)-Joint VentureJan 10, 2025
Jan 10, 2025Closure of Trading WindowDec 31, 2024
Dec 31, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 02, 2024
Dec 02, 2024Statement Of Deviation(S) Or Variation(S), If Any, Of Utilization Of Proceeds Received From Qualified Institutions Placement (QIP) Under Regulation 32 Of SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015.Nov 13, 2024
Nov 13, 2024Monitoring Agency Report For The Quarter Ended 30Th September, 2024 - QIP Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015Nov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 06, 2024
Nov 06, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 29, 2024
Oct 29, 2024Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 28, 2024
Oct 28, 2024Announcement under Regulation 30 (LODR)-Change in ManagementOct 28, 2024
Oct 28, 2024Financial Results For The Quarter And Half Year Ended On 30Th September, 2024.Oct 28, 2024
Oct 28, 2024Board Meeting Outcome for Outcome Of The Board Meeting Of The Company In Compliance Of Regulation 30 And 33 Of SEBI (LODR) Regulations, 2015Oct 28, 2024
Oct 28, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 24, 2024
Oct 24, 2024Board Meeting Intimation for Board Meeting Intimation Scheduled To Be Held On 28Th October, 2024.Oct 19, 2024
Oct 19, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 15, 2024
Oct 15, 2024Closure of Trading WindowSep 30, 2024
Sep 30, 2024Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 28, 2024
Sep 28, 2024Announcement under Regulation 30 (LODR)-Change in DirectorateSep 26, 2024
Sep 26, 2024Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2024
Sep 26, 2024Technical Indicators
RSI(14)
Neutral 39.97
ATR(14)
Less Volatile 94.05
STOCH(9,6)
Neutral 25.11
STOCH RSI(14)
Oversold 0.00
MACD(12,26)
Bearish -29.37
ADX(14)
Weak Trend 17.10
UO(9)
Bearish 40.40
ROC(12)
Downtrend But Slowing Down -2.86
WillR(14)
Oversold -84.55
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth | 0 | 0.00% | -1.31% | 0.00% | Apr 2025 | |
 SBI Healthcare Opportunities Fund Direct Plan-Growth | 540000 | 3.79% | 0.43% | 0.47% | Apr 2025 | |
 Quant Small Cap Fund Direct Plan-Growth | 3143260 | 3.09% | 0.25% | 0.37% | Apr 2025 | |
 Invesco India ESG Integration Strategy Fund Direct - Growth | 44065 | 2.43% | 0.24% | 0.37% | Apr 2025 | |
 Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth | 1682 | 1.79% | 0.24% | 0.22% | Apr 2025 | |
| Invesco India ELSS Tax Saver Fund Direct-Growth | 249456 | 2.36% | 0.24% | 0.31% | Apr 2025 | |
 Tata Nifty MidSmall Healthcare Index Fund Direct - Growth | 9354 | 1.79% | 0.23% | 0.21% | Apr 2025 | |
 WhiteOak Capital Pharma and Healthcare Fund Direct - Growth | 18414 | 1.48% | -0.19% | -0.28% | Apr 2025 | |
| Invesco India Manufacturing Fund Direct-Growth | 50022 | 1.67% | 0.17% | 0.20% | Apr 2025 | |
| Invesco India Multicap Fund Direct-Growth | 246785 | 1.68% | 0.16% | 0.19% | Apr 2025 | |
 Bank of India Small Cap Fund Direct-Growth | 96500 | 1.52% | 0.14% | 0.11% | Apr 2025 | |
| Bank of India ELSS Tax Saver Direct-Growth | 59200 | 1.15% | 0.14% | 0.13% | Apr 2025 | |
| Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth | 0 | 0.00% | -0.13% | -0.11% | Apr 2025 | |
 UTI Flexi Cap Fund Direct-Growth | 1452175 | 1.48% | 0.13% | 0.19% | Apr 2025 | |
| WhiteOak Capital ESG Best-In-Class Strategy Fund Direct-Growth | 2677 | 1.11% | 0.10% | 0.17% | Apr 2025 | |
 Edelweiss Nifty500 Multicap Momentum Quality 50 Index Fund Direct-Growth | 6961 | 0.87% | 0.09% | 0.15% | Apr 2025 | |
| UTI Healthcare Fund Direct-Growth | 28000 | 0.69% | 0.09% | 0.03% | Apr 2025 | |
| WhiteOak Capital Flexi Cap Fund Direct - Growth | 220830 | 1.21% | 0.09% | 0.09% | Apr 2025 | |
| WhiteOak Capital ELSS Tax Saver Fund Direct - Growth | 16495 | 1.18% | 0.09% | 0.05% | Apr 2025 | |
| Quant Active Fund Direct-Growth | 264798 | 0.71% | 0.09% | 0.16% | Apr 2025 | |
| Bank of India Mid & Small Cap Equity & Debt Fund Direct-Growth | 32000 | 0.75% | 0.08% | 0.08% | Apr 2025 | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 548 | 0.78% | 0.08% | 0.10% | Apr 2025 | |
| SBI Nifty Smallcap 250 Index Fund Direct - Growth | 27962 | 0.57% | 0.07% | 0.07% | Apr 2025 | |
 Axis Nifty500 Momentum 50 Index Fund Direct-Growth | 1365 | 0.60% | 0.07% | 0.09% | Apr 2025 | |
 HDFC Nifty Smallcap 250 Index Fund Direct-Growth | 9234 | 0.57% | 0.07% | 0.06% | Apr 2025 |
About Poly Medicure
Poly Medicure Limited is an Indian medical device manufacturer founded in 1995. The company produces over 130 SKUs of medical devices across various product verticals including infusion therapy, oncology, anesthesia, respiratory care, urology, gastroenterology, blood management, surgery, and dialysis. Poly Medicure operates ten manufacturing facilities across India, China, Egypt, and Italy, with seven in India, one in China through a wholly-owned subsidiary, one in Egypt through an associate, and one in Italy through a step-down subsidiary. The company exports to over 110 countries through a network of more than 220 distributors. Poly Medicure's facilities are accredited with international quality certifications, including ISO 9001:2015 and EN ISO 13485:2016. The company has an R&D center in Faridabad, Haryana, approved by DSIR, focusing on developing new products and improving existing processes. Poly Medicure holds over 375 patents for its products in various therapeutic areas.
Website
Chairperson NameDevendra Raj Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
